Strata Critical Medical, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission, reporting a net loss from continuing operations of $7,615 thousand for the three months ended September 30, 2026.

Key Highlights

  • Revenue of $74,081 thousand for the three months ended September 30, 2026, compared to $49,298 thousand in the same period of 2025, according to the filing.
  • Net loss of $7,615 thousand for Q3 2026, versus net income of $57,416 thousand in Q3 2025, which the filing notes included $67,073 thousand of net income from discontinued operations.
  • Accumulated deficit of $161,528 thousand as of September 30, 2026, up from $145,551 thousand at December 31, 2025.
  • Total assets of $328,884 thousand as of September 30, 2026, compared to $325,472 thousand at December 31, 2025.
  • 89,317,857 shares of common stock issued as of September 30, 2026, up from 86,702,183 at December 31, 2025.
  • Cash and cash equivalents of $35,136 thousand at September 30, 2026, compared to $30,968 thousand at December 31, 2025.

Strata Critical Medical Q3 2026 Financial Results and Balance Sheet Overview

According to the filing, Strata Critical Medical, Inc. (NASDAQ:SRTA) reported revenue of $74,081 thousand for the three months ended September 30, 2026, representing an increase from $49,298 thousand in the comparable prior-year quarter. Cost of revenue for Q3 2026 was $57,261 thousand, yielding a gross profit of $16,820 thousand. For the nine months ended September 30, 2026, revenue was $213,971 thousand versus $130,354 thousand for the same period of 2025, the filing disclosed.

The company reported a net loss from continuing operations of $7,615 thousand for the three months ended September 30, 2026, compared to a net loss from continuing operations of $9,657 thousand in Q3 2025. The filing notes that Q3 2025 net income of $57,416 thousand included $67,073 thousand in net income from discontinued operations, which had no comparable contribution in Q3 2026. Total operating expenses for the quarter were $20,651 thousand, which included amortization of intangible assets of $5,511 thousand. Other non-operating items included a realized loss from sales of short-term investments of $1,281 thousand and a change in fair value of assets and other liabilities of negative $2,649 thousand for the quarter.

The balance sheet as of September 30, 2026 showed total stockholders' equity of $276,375 thousand, down from $279,072 thousand at December 31, 2025. Goodwill increased to $101,918 thousand from $88,210 thousand over the same period, and intangible assets, net rose to $58,830 thousand from $47,502 thousand, according to the filing. The registrant is classified as an accelerated filer and reported 89,319,857 shares outstanding as of October 26, 2026.

What Was Disclosed

Strata Critical Medical filed its quarterly report covering the period ended September 30, 2026, disclosing revenue growth, a continuing net loss of $7,615 thousand for the quarter, an accumulated deficit of $161,528 thousand, and total assets of $328,884 thousand as of the period end.